Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role
of allogeneic stem cell transplantation have been demonstrated in these patients. This
clinical trial is studying the efficacy and safety of busulfan plus fludarabine as
conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and
NK/T-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies
including autologous transplantation.